ELElly I. Lewerissa

Elly I. Lewerissa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elly I. Lewerissa has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissecting the sources of variation in neuronally differentiated iPSC lines through multi-omics analysis

    by Casper de Visser, Lisa Rahm, Elly Lewerissa, Rachel Mijdam, Cenna Doornbos, Junda Huang, Luke O’GOrman, Firdaws Badmus, Clara D.M. van Karnebeek, Catharina G. Faber, et al.

    Summary: Induced pluripotent stem cells (iPSCs) are widely used as patient-specific disease models, yet substantial unexplained variability in molecular and functional readouts limits their reliability. Here, we systematically investigated the sources of variation in iPSC-derived neurons for three rare genetic disorders: Myotonic Dystrophy Type 1, chromodomain-DNA-helicase-binding protein 2-related disorder and N -acetylneuraminic acid synthase deficiency. This was performed by profiling multi-omics layers: genomics, epigenomics, transcriptomics, proteomics, metabolomics and lipidomics. Our study found that clonal variability was comparable to inter-patient differences and that neuronal differentiation state and nutrient-driven metabolic activity emerged as dominant contributors to variability observed across omics layers. Clonal differences could partly be attributed to stochastic differences in DNA methylation established during reprogramming. By modeling and correcting the observed variation, we improved the detection of disease-associated molecular signatures. Our study provides guidelines for improved study design and data analysis to minimize variability, enabling robust biomarker discovery and reliable iPSC-based disease modeling.


  • Open Access

    MEA-LINK identifies the CCL4-CCR5 axis in neuronal hyperactivity control by human microglia

    by Annika Mordelt, Nicky Scheefhals, Imke M. E. Schuurmans, Koen Slottje, Mariela Cano Rivera, Marina P. Hommersom, Ao Huang, Leon Bichmann, Elly I. Lewerissa, Eline J. H. van Hugte, et al.

    Microglia, the resident immune cells of the brain, act along a spectrum to maintain CNS homeostasis, respond to perturbations, and control neuronal activity. Disentangling the molecular mechanisms of human microglia-neuron crosstalk remains challenging due to the context-dependent, dynamic nature of their interaction. We introduce MEA-LINK, a systems-approach leveraging natural variation to screen for immune modulators of neuronal activity. This multi-modal platform integrates human induced pluripotent stem cell (hiPSC) technology with micro-electrode array (MEA) recordings and proteomic analyses of secreted immune factors, allowing for longitudinal samples and correlations across modalities. We applied MEA-LINK to explore microglia-neuron interactions during development and hyperactivity challenges. We show that human microglia accelerate neuronal network development and rescue hyperactive network phenotypes. Linking the secretome adaptations to neuronal network activity variations, we identified CCL4 as a top candidate in microglia-mediated hyperactivity control. Then, we functionally validated the context-dependent role of microglial CCL4 to neuronal CCR5 signaling in human neuronal networks. Our findings support a neuron-specific function of chemokines and their receptors in the brain and provide a new perspective for immune signaling in neuronal hyperactivity control. The MEA-LINK platform thus offers a foundation for comprehensive, systematic studies of human microglia-neuron interactions. Highlights: MEA-LINK integrates micro-electrode array recordings with proteomics of longitudinal samples to identify immune modulators of neuronal activity. Human microglia rescue neuronal hyperactivity induced by pharmacological and genetic challenges. Microglial CCL4 dampens neuronal activity via CCR5 signaling in a context-dependent manner. Graphical


  • Open Access

    CHD2 Dosage Ties Autolysosomal Pathway to Cortical Maturation in Disease and Evolution

    by Oliviero Leonardi, Elly Lewerissa, Davide Aprile, Tahsin Stefan Barakat, Lorenza Culotta, Ruizhi Deng, Linda Haazen, Katrin Linda, Marian Majoie, Annika Mordelt, et al.

    The relatively slow pace of cortical development in humans has long been a topic of investigation. Studies seeking to understand the underlying mechanisms have mostly focused on neurogenetic comparisons with extant species. Here we ask if developmental tempo differences may have also existed between us and our extinct relatives for whom genomes are available. To do so, we nominate a sapiens -specific derived allele, virtually fixed in contemporary populations, which resides in an enhancer region active during early cortical development. The single nucleotide variant is predicted to significantly affect CHD2 expression, a chromatin remodeler known to play an important role in neural development and for which haploinsufficiency is associated with epilepsy and autism. We leverage patient induced pluripotent stem lines (iPSC) and engineered iPSCs in which we reintroduced the ancestral allele and generated heterozygous loss-of-function mutations. We reveal that CHD2 deficiency impairs lysosomal acidification and autophagosome flux. In contrast, ancestralized lines, which we find express higher levels of CHD2, exhibit enhanced lysosomal function and consequently accelerated autophagosome flux, consistent with our observations in chimpanzee and bonobo lines. This set of findings demonstrates that CHD2 dosage critically regulates the autolysosomal pathway. Through deep phenotyping of cortical organoid and neuron cultures, we show that the CHD2-modulated autolysosomal pathway impacts the timing of developmental programs, acquisition of neuronal functional properties and circuit maturation. Finally, we validate an estrogen-dependent rewiring of CHD2 regulation in the evolution of our lineage, providing a mechanistic understanding of how a single nucleotide variant in a regulatory region contributed to the modern pace of neuronal development and maturation. Together, our findings establish CHD2 as a regulator in setting neurodevelopmental tempo via the autolysosomal pathway.


  • Open Access

    Neuronal autophagosomes are transported to astrocytes for degradation

    by K. Linda, I.M.E. Schuurmans, H. Smeenk, K. Vints, M. Negwer, N. Peredo, E.I. Lewerissa, J. Swerts, M. Hoekstra, A. Mordelt, et al.

    Autophagy is a vital catabolic process responsible for the degradation of cytosolic components, playing a key role in cellular homeostasis and survival. At synapses, autophagy is crucial for regulating neuronal activity and utilizes a specialized machinery. While considerable progress has been made in understanding the initiation of autophagy and autophagosome formation, the mechanisms governing the clearance of autophagosomes from synaptic sites remain poorly understood. Here, we identify a novel pathway in which astrocytes actively participate in the clearance of pre-synaptic autophagosomes. Using neurons derived from human induced pluripotent stem cell (hiPSC) lines expressing fluorescent autophagy markers and chimeric mouse models, we demonstrate that neuronal autophagosomal vesicles are physically transferred to astrocytes, a process that is enhanced when synaptic activity is suppressed. Autophagosome transfer does not require direct physical cellular contact, but it does require Dynamin and cholesterol-dependent endocytosis for the internalized neuronal autophagosomes to ultimately fuse with astrocytic lysosomes. Our findings reveal a previously unrecognized mechanism of neuronal autophagosome clearance that does not require slow axonal retrograde transport but their transfer to nearby astrocytes.


  • Open Access

    Integrative transcriptomics and electrophysiological profiling of hiPSC-derived neurons identifies novel druggable pathways in Koolen-de Vries Syndrome

    by Anouk H.A. Verboven, Sofia Puvogel, Nikki Kolsters, Brooke Latour, Katrin Linda, Elly I. Lewerissa, Rachel Mijdam, Emma Dyke, Denise Duineveld, Martijn Zoodsma, et al.

    Koolen-de Vries Syndrome (KdVS) is a neurodevelopmental disorder (NDD) with no treatment options due to a lack of understanding of its underlying pathophysiology. To investigate neuronal activity in KdVS, human induced pluripotent stem cell (hiPSC)-derived neurons from KdVS and control subjects were cultured on microelectrode arrays (MEAs). Our study identified reduced network burst rates, indicating disorganized network activity in KdVS neurons. To bridge molecular and functional aspects of the syndrome, we developed an experimental framework, MEA-seq, that integrates network activity measurements with high-throughput transcriptome profiling. This approach identified a negative correlation between the expression of the NDD-associated gene CLCN4 and the network burst rate. Consequently, knockdown of CLCN4 in KdVS neurons restored the activity to control level, confirming a causal relationship between increased CLCN4 expression and reduced network burst rate. Additionally, we identified a positive correlation between mitochondrial gene expression and the network burst rate, and identified impaired mitochondrial function in KdVS hiPSC-derived neurons. The transcriptomic signature of KdVS neurons was then used for computational screening against drug perturbation signatures of the LINCS Consortium database, predicting other drug targets and compounds capable of reversing the expression of affected genes in KdVS neurons. We selected 10 compounds for experimental validation, identifying the antioxidant phloretin and the Rho-kinase inhibitor fasudil as potential candidates for restoring the network activity dysfunction in KdVS. We conclude that the integrative molecular and electrophysiological of hiPSC-derived neurons with MEA-seq has excellent potential for identifying novel drugs and druggable pathways for KdVS and other NDDs.


  • Open Access

    CACNA1A haploinsufficiency leads to reduced synaptic function and increased intrinsic excitability

    by Marina P. Hommersom, Nina Doorn, Sofía Puvogel, Elly I. Lewerissa, Annika Mordelt, Ummi Ciptasari, Franziska Kampshoff, Lieke Dillen, Ellen van Beusekom, Astrid Oudakker, et al.

    Haploinsufficiency of the CACNA1A gene, encoding the pore-forming α1 subunit of P/Q-type voltage-gated calcium channels, is associated with a clinically variable phenotype ranging from cerebellar ataxia, to neurodevelopmental syndromes with epilepsy and intellectual disability. To understand the pathological mechanisms of CACNA1A loss-of-function variants, we characterized a human neuronal model for CACNA1A haploinsufficiency, by differentiating isogenic induced pluripotent stem cell lines into glutamatergic neurons, and investigated the effect of CACNA1A haploinsufficiency on mature neuronal networks through a combination of electrophysiology, gene expression analysis, and in silico modeling. We observed an altered network synchronization in CACNA1A +/− networks alongside synaptic deficits, notably marked by an augmented contribution of GluA2-lacking AMPA receptors. Intriguingly, these synaptic perturbations coexisted with increased non-synaptically driven activity, as characterized by inhibition of NMDA and AMPA receptors on micro-electrode arrays. Single-cell electrophysiology and gene expression analysis corroborated this increased intrinsic excitability through reduced potassium channel function and expression. Moreover, we observed partial mitigation of the CACNA1A +/− network phenotype by 4-aminopyridine, a therapeutic intervention for episodic ataxia type 2. In summary, our study pioneers the characterization of a human induced pluripotent stem cell-derived neuronal model for CACNA1A haploinsufficiency, and has unveiled novel mechanistic insights. Beyond showcasing synaptic deficits, this neuronal model exhibited increased intrinsic excitability mediated by diminished potassium channel function, underscoring its potential as a therapeutic discovery platform with predictive validity.


  • Open Access

    SCN1A -deficient hiPSC-derived excitatory neuronal networks display mutation-specific phenotypes

    by Eline J.H. van Hugte, Elly I. Lewerissa, Ka Man Wu, Giulia Parodi, Torben van Voorst, Naoki Kogo, Jason M. Keller, Dirk Schubert, Helenius J. Schelhaas, Judith Verhoeven, et al.

    Dravet syndrome is a severe epileptic encephalopathy, characterized by (febrile) seizures, behavioral problems and developmental delay. 80% of Dravet syndrome patients have a mutation in SCN1A , encoding Na V 1.1. Milder clinical phenotypes, such as GEFS + (generalized epilepsy with febrile seizures plus), can also arise from SCN1A mutation s . Predicting the clinical phenotypic outcome based on the type of mutation remains challenging, even when the same mutation is inherited within one family. Both this clinical and genetic heterogeneity add to the difficulties of predicting disease progression and tailored prescription of anti-seizure medication. A better understanding of the neuropathology of different SCN1A mutations, might give insight in differentiating the expected clinical phenotype and best fit treatment choice. Initially it was recognized that loss of Na + -current in inhibitory neurons specifically resulted in disinhibition and consequently seizure generation. However, the extent to which excitatory neurons contribute to the pathophysiology is currently debated, and might depend on the patient clinical phenotype or the specific mutation in SCN1A . To examine the genotype-phenotype correlations of SCN1A mutations in relation to excitatory neurons, we investigated a panel of patient-derived excitatory neuronal networks differentiated on multi-electrode arrays. We included patients with different clinical phenotypes, harboring different mutations in SCN1A , plus a family where the same mutation leads to both GEFS+ and Dravet syndrome. We hitherto describe a previously unidentified functional excitatory neuronal network phenotype in the context of epilepsy, which corresponded to seizurogenic network prediction patterns elicited by proconvulsive compounds. We find that excitatory neuronal networks were differently affected, dependent on the type of S CN1A mutation, but not on clinical severity. Specifically, pore domain mutations could be distinguished from voltage sensing domain mutations. Furthermore, all patients showed aggravated neuronal network responses upon febrile temperatures. While the basal neuronal network phenotypes could not be distinguished based on patient clinical severity, retrospective drug screening revealed that anti-seizure medication only affected GEFS+ patient-, but not Dravet patient-derived neuronal networks in a patient specific and clinically relevant manner. In conclusion, our results indicate a mutation-specific excitatory neuronal network phenotype, which recapitulates the foremost clinically relevant features, providing future opportunities for precision therapies. Highlights: Human stem cell derived excitatory neurons are affected by mutations in SCN1A and display mutation-specific, but not clinical phenotype specific, neuronal network phenotypes The neuronal network phenotype we describe corresponds to seizurogenic network prediction patterns in vitro Excitatory neuronal networks respond to Dravet syndrome clinically relevant triggers, like febrile temperatures and Dravet-contraindicated ASM Carbamazepine Retrospective drug screening revealed that GEFS+ neuronal networks, but not Dravet neuronal networks respond to ASM in a patient-specific and clinical relevant manner